Online inquiry

IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ225MR)

This product GTTS-WQ225MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Esophagitis eosinophilic research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ225MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3353MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AT-004
GTTS-WQ5517MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ15376MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TRU-016
GTTS-WQ14053MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3918
GTTS-WQ6624MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ6975MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ETI-204
GTTS-WQ15743MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VX-15
GTTS-WQ9382MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Interleukin 2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW